Journal article

Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation

Marie-Claude Gingras, Kyle R Covington, David K Chang, Lawrence A Donehower, Anthony J Gill, Michael M Ittmann, Chad J Creighton, Amber L Johns, Eve Shinbrot, Ninad Dewal, William E Fisher, Christian Pilarsky, Robert Gruetzmann, Michael J Overman, Nigel B Jamieson, George Van Buren, Jennifer Drummond, Kimberly Walker, Oliver A Hampton, Liu Xi Show all

CELL REPORTS | CELL PRESS | Published : 2016


The ampulla of Vater is a complex cellular environment from which adenocarcinomas arise to form a group of histopathologically heterogenous tumors. To evaluate the molecular features of these tumors, 98 ampullary adenocarcinomas were evaluated and compared to 44 distal bile duct and 18 duodenal adenocarcinomas. Genomic analyses revealed mutations in the WNT signaling pathway among half of the patients and in all three adenocarcinomas irrespective of their origin and histological morphology. These tumors were characterized by a high frequency of inactivating mutations of ELF3, a high rate of microsatellite instability, and common focal deletions and amplifications, suggesting common attribute..

View full abstract


Awarded by HGSC-BCM: NHGRI

Awarded by CPRIT grant

Awarded by Dan L. Duncan Cancer Center NIH P30 Cancer Center

Awarded by Australian Pancreatic Cancer Genome Initiative: National Health and Medical Research Council of Australia (NHMRC)

Awarded by Cancer Research UK

Awarded by Cancer Council NSW

Awarded by Cancer Institute NSW

Awarded by Italian Ministry of Research

Awarded by Associazione Italiana Ricerca Cancro

Awarded by Fondazione Italiana Malattie Pancreas - Ministero Salute

Awarded by Wilhelm Sander Stiftung

Awarded by NIH

Awarded by Academy of Medical Sciences (AMS)

Awarded by Pancreatic Cancer UK



Funding Acknowledgements

We acknowledge the following funding support: HGSC-BCM: NHGRI U54 HG003273 and CPRIT grant RP101353-P7 (Tumor Banking for Genomic Research and Clinical Translation Site 1); D.W.A. CPRIT grant RPI21018; M.M.I. and C.J.C.: Dan L. Duncan Cancer Center NIH P30 Cancer Center support grant (P30 CA125123) supporting the BCM Human Tissue Acquisition and Pathology Core and the Biostatistics and Bioinformatics Core; M.J.O.: Kavanagh Family Foundation. Australian Pancreatic Cancer Genome Initiative: National Health and Medical Research Council of Australia (NHMRC; 631701, 535903, 427601); Queensland Government (NIRAP); University of Queensland; Institute for Molecular Bioscience; Cancer Research UK (C596/A18076, C29717/A17263); University of Glasgow; Australian Government: Department of Innovation, Industry, Science and Research (DIISR); Australian Cancer Research Foundation (ACRF); Cancer Council NSW: (SRP06-01, SRP11-01.ICGC); Cancer Institute NSW: (10/ECF/2-26; 06/ECF/1-24; 09/CDF/2-40; 07/CDF/1-03; 10/CRF/1-01, 08/RSA/1-15, 07/CDF/1-28, 10/CDF/2-26,10/FRL/2-03, 06/RSA/1-05, 09/RIG/1-02, 10/TPG/1-04, 11/REG/1-10, 11/CDF/3-26); Garvan Institute of Medical Research; Avner Nahmani Pancreatic Cancer Research Foundation; Howat Foundation; R.T. Hall Trust; Petre Foundation; Philip Hemstritch Foundation; Gastroenterological Society of Australia (GESA); American Association for Cancer Research (AACR) Landon Foundation - INNOVATOR Award; Royal Australasian College of Surgeons (RACS); Royal Australasian College of Physicians (RACP); Royal College of Pathologists of Australasia (RCPA); Italian Ministry of Research (Cancer Genome Project FIRB RBAP10AHJB); Associazione Italiana Ricerca Cancro (12182); Fondazione Italiana Malattie Pancreas - Ministero Salute (CUP_J33G13000210001); Wilhelm Sander Stiftung 2009.039.2; NIH grant P50 CA62924. See the Supplemental Information for further acknowledgments.